Cabozantinib (Standard) is the analytical standard of Cabozantinib, a potent and orally active inhibitor of VEGFR2 and MET with IC50 values of 0.035 nM and 1.3 nM, respectively. It also significantly inhibits KIT, RET, AXL, TIE2, and FLT3. This product exhibits antiangiogenic activity, disrupting tumor vasculature and promoting apoptosis in tumor and endothelial cells. It is intended for research and analytical applications.
- It is the analytical standard for Cabozantinib.
- It serves as a potent and orally active inhibitor of VEGFR2 and MET.
- It demonstrates strong inhibition of various other kinases including KIT, RET, AXL, TIE2, and FLT3.
- It possesses antiangiogenic properties.
- It disrupts tumor vasculature and induces apoptosis in tumor and endothelial cells.
- It is suitable for research and analytical applications, including qualitative, quantitative, and methodological research experiments in HPLC, GC, and MS.